Neil M. Iyengar, MD, on Cancer Risk Reduction: Effects of Menopausal HRT and GLP-1 RAs
2025 ASCO Annual Meeting
Neil M. Iyengar, MD, of Memorial Sloan Kettering Cancer Center, reviews several studies that aimed to answer two questions: does menopausal hormone therapy (HRT) impact overall survival and breast cancer–specific mortality in younger women diagnosed with high-risk disease (Abstract 10506); and do GLP-1 receptor agonists (GLP-1 RAs), a class of weight-loss medications, have cancer risk reduction properties (Abstracts 10507 and 10508).
The ASCO Post Staff
David Allen Barbie, MD, of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, reviews specific clinical and molecular features of early progressors and long-term progression-free survivors from the phase III ADRIATIC trial, which assessed consolidation durvalumab vs placebo after concurrent chemoradiotherapy for limited-stage small cell lung cancer (Abstract 8014).
The ASCO Post Staff
Karen Eubanks Jackson, Founder and Chief Executive Officer of Sisters Network Inc. and recipient of the 2025 ASCO Patient Advocate Award, discusses her 30-year-long effort to support patients with breast cancer in the Black community. Sisters Network is focused on raising awareness of early screening for breast cancer, providing financial assistance, and addressing the disparities Black women face in breast cancer care and outcomes.
The ASCO Post Staff
Frank A. Sinicrope, MD, of Mayo Clinic Rochester, reviews findings from the randomized Alliance A021502/ATOMIC trial, which studied standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III DNA mismatch repair–deficient (dMMR) colon cancer (LBA1).
The ASCO Post Staff
Nitin Jain, MD, Professor in the Department of Leukemia and Director of the Leukemia CAR-T Program at The University of Texas MD Anderson Cancer Center, shares his expert point of view on data presented on front-line therapies for chronic lymphocytic leukemia (CLL) presented at the 2025 ASCO Annual Meeting.
The ASCO Post Staff
Mafalda Oliveira, MD, PhD, of Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, discusses findings on the incidence and management of hyperglycemia in a subset of patients with prediabetes and/or obesity included in the phase I trial of inavolisib alone and in combination with endocrine therapy with or without palbociclib for PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer (Abstract 1004).
